Skip to main content
Top

20-11-2017 | Breast cancer | Article

Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study

Journal: Breast Cancer Research and Treatment

Authors: O. Brouckaert, K. Van Asten, A. Laenen, A. Soubry, A. Smeets, I. Nevelstreen, I. Vergote, H. Wildiers, R. Paridaens, E. Van Limbergen, C. Weltens, P. Moerman, G. Floris, P. Neven, On behalf of Multidisciplinary breast centre Leuven

Publisher: Springer US

Abstract

Purpose

Evidence suggests that premenopausal obesity decreases and postmenopausal obesity increases breast cancer risk. Because it is not well known whether this is subtype dependent, we studied the association between body mass index (BMI) and age at breast cancer diagnosis, or the probability of being diagnosed with a specific breast cancer phenotype, by menopausal status.

Methods

All patients with non-metastatic operable breast cancer from the University Hospital Leuven diagnosed between January 1, 2000 and December 31, 2013 were included (n = 7020) in this cross-sectional study. Linear models and logistic regression were used for statistical analysis. Allowing correction for age-related BMI-increase, we used the age-adjusted BMI score which equals the difference between a patient’s BMI score and the population-average BMI score corresponding to the patient’s age category.

Results

The quadratic relationship between the age-adjusted BMI and age at breast cancer diagnosis (p = 0.0207) interacted with menopausal status (p < 0.0001); increased age at breast cancer diagnosis was observed with above-average BMI scores in postmenopausal women, and with below-average BMI scores in premenopausal women. BMI was linearly related to the probabilities of Luminal B and HER2-like breast cancer phenotypes, but only in postmenopausal women. The relative changes in probabilities between both these subtypes mirrored each other.

Conclusion

BMI associates differently before and after menopause with age at breast cancer diagnosis and with the probability that breast cancer belongs to a certain phenotype. The opposite effect of increasing BMI on relative frequencies of Luminal B and HER2-like breast cancers suggests a common origin.
Literature
1.
DeSantis CE, Lin CC, Mariotto AB et al (2014) Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64:252–271CrossRefPubMed
2.
WHO (2011) World Health Statistics 2011. World Health Organization, Geneva
3.
Bhaskaran K, Douglas I, Forbes H et al (2014) Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5 24 million UK adults. Lancet 384(9945):755–765CrossRefPubMedPubMedCentral
4.
Yang XR, Chang-Claude J, Goode EL et al (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 103(3):250–263CrossRefPubMed
5.
James WP, Jackson-Leach R, Ni Mhurchu C et al. WHO report Comparative Quantification of Health Risks, Chapter 8 Overweight and obesity (high body mass index), 497–596
6.
Dowsett M, Folkerd E (2015) Reduced progesterone levels explain the reduced risk of breast cancer in obese premenopausal women: a new hypothesis. Breast Cancer Res Treat 149(1):1–4CrossRefPubMed
7.
Nevadunsky NS, Van Arsdale A, Strickler HD et al (2014) Obesity and age at diagnosis of endometrial cancer. Obstet Gynecol 124(2 Pt 1):300–306CrossRefPubMed
8.
Kounelis S, Kapranos N, Kouri E et al. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 13(4): 379–88 (2000); Int J Cancer 135(11): 2678–86 (2014)
9.
Peacock SL, White E, Daling JR et al (1999) Relation between obesity and breast cancer in young women. Am J Epidemiol 149(4):339–346CrossRefPubMed
10.
Tehard B, Clavel-Chapelon F (2006) Several anthropometric measurements and breast cancer risk: results of the E3 N cohort study. Int J Obes 30(1):156–163CrossRefPubMedCentral
11.
Millikan RC, Newman B, Tse CK et al (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109(1):123–139CrossRefPubMed
12.
Suzuki R, Orsini N, Saji S et al (2009) Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status—a meta-analysis. Int J Cancer 124(3):698–712CrossRefPubMed
13.
Horwitz KB, Koseki Y, McGuire WL (1978) Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 103(5):1742–1751CrossRefPubMed
14.
Huang HJ, Neven P, Drijkoningen M et al (2005) Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. Breast Cancer Res Treat 91(1):81–87CrossRefPubMed
15.
Van Mieghem T, Leunen K, Pochet N et al (2007) Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age. Breast Cancer Res Treat 106(1):127–133CrossRefPubMed
16.
Pathak DR (2002) Dual effect of first full term pregnancy on breast cancer risk: empirical evidence and postulated underlying biology. Cancer Causes Control 13:295–298CrossRefPubMed
17.
Opdahl S, Alsaker MDK, Janszky I, Romundstad PR, Vatten LJ (2011) Joint effects of nulliparity and other breast cancer risk factors. Br J Cancer 105:731–736CrossRefPubMedPubMedCentral
18.
Brouckaert O, Laenen A, Vanderhaegen J et al (2012) Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. Ann Oncol 23(10):2578–2584CrossRefPubMed
19.
Drieskens S, Charafeddine R, Demarest S, Gisle L, Tafforeau J, Van der Heyden J Health Interview Survey, Belgium, 1997–2001–2004–2008–2013: Health Interview Survey Interactive Analysis. Brussels: WIV-ISP. https://​hisia.​wiv-isp.​be/​
20.
Maruthur NM, Bolen S, Brancati FL (2009) Clark JM Obesity and mammography: a systematic review and meta-analysis. J Gen Intern Med 24(5):665–677. https://​doi.​org/​10.​1007/​s11606-009-0939-3 CrossRefPubMedPubMedCentral
21.
Martinez ME, Cruz GI, Brewster AM, Bondy ML, Thompson PA (2010) What can we learn about disease etiology from case-case analyses? Lessons from breast cancer. Cancer Epidemiol Biomark Prev 19:2710–2714CrossRef
22.
Biglia N, Peano E, Sgandurra P et al (2013) Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women. Gynecol Endocrinol 29(3):263–267CrossRefPubMed
23.
Molyneux G, Geyer FC, Magnay FA et al (2010) BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7(3):403–417CrossRefPubMed
24.
Prat Aleix, Baselga José (2008) The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol 5(9):531–542CrossRefPubMed
25.
Countercurrents Series, Narod SA (2012) Disappearing breast cancers. Curr Oncol 19(2):59–60
26.
Phipps AI, Malone KE, Porter PL, Daling JR, Li CI (2008) Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 17(8):2078–2086CrossRefPubMedPubMedCentral
27.
Garcia-Closas M, Brinton LA, Lissowska J et al (2006) Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer 95(1):123–129CrossRefPubMedPubMedCentral
28.
Vineis P, Schatzkin A, Potter JD (2010) Models of carcinogenesis: an overview. Carcinogenesis 31:1703–1709CrossRefPubMedPubMedCentral
29.
Pan Hongchao, Gray Richard G, on behalf of the Early Breast Cancer Trialists’ Collaborative Group (2014) Effect of obesity in premenopausal ER + early breast cancer: EBCTCG data on 80,000 patients in 70 trials. J Clin Oncol 32:503
30.
Petekkaya I, Sahin U, Gezgen G et al (2013) Association of breast cancer subtypes and body mass index. Tumori 99(2):129–133PubMed
31.
Miyagawa Y, Miyake T, Yanai A et al. (2013) Association of body mass index with risk of luminal A but not luminal B estrogen receptor-positive and HER2-negative breast cancer for postmenopausal Japanese women. Breast Cancer
32.
Song Q, Huang R, Li J, Fan J et al (2013) The diverse distribution of risk factors between breast cancer subtypes of ER, PR and HER2: a 10-year retrospective multi-center study in China. PLoS ONE 8(8):e72175CrossRefPubMedPubMedCentral
33.
Yanai A, Miyagawa Y, Murase K et al (2014) Influence of body mass index on clinicopathological factors including estrogen receptor, progesterone receptor, and Ki67 expression levels in breast cancers. Int J Clin Oncol 19(3):467–472CrossRefPubMed